Social Interaction Perceptions for Mental Illness
Trial Summary
What is the purpose of this trial?
The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions among these experiences in daily life and how they, and their neurobehavioral predictors, are linked to day-to-day functioning. The findings of this project could provide novel targets for therapeutics aimed at improving functioning and overall quality of life in individuals with serious mental illnesses, as well as quantitative phenotypes for use in early detection efforts.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've had a recent change in medication.
What data supports the effectiveness of the treatment EMA for improving social interaction perceptions in mental illness?
Is the treatment generally safe for humans?
How does this treatment for mental illness differ from other treatments?
This treatment focuses on changing social perceptions and reducing stigma associated with mental illness, which is different from traditional treatments that often focus on managing symptoms through medication or therapy. By addressing social exclusion and stigma, it aims to improve social interactions and acceptance for individuals with mental illness.1112131415
Research Team
Daphne J Holt, MD, PhD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for individuals aged 18-55 who have experienced serious mental illnesses like psychosis, schizophrenia, or mood disorders. Participants must speak English fluently and not have had any recent medication changes or acute symptoms. They can't join if they've used substances in the past 6 months, have neurological issues, MRI scan exclusions like metal implants, or severe claustrophobia.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Ecological Momentary Assessment
EMA collected daily (4x/day) for two weeks to measure transient changes in social isolation and loneliness
Longitudinal Assessment
Measure stable neural and behavioral predictors of social isolation and loneliness, and their impact on real-world functioning
Follow-up
Participants are monitored for safety and effectiveness after the main assessments
Treatment Details
Interventions
- EMA
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Boston University
Collaborator